Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Kaplan-Meier estimation
Time-to-event endpoints
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
All oncology trials
232 results
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SKYSCRAPER-02Independent statistical analysis of SKYSCRAPER-02, a randomized phase 3 trial of tiragolumab plus atezolizumab with carboplatin and etoposide versus placebo plus atezolizumab with carboplatin and etoposide in untreated extensive-stage small cell lung…
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SOFTIndependent statistical analysis of the SOFT phase 3 trial of tamoxifen, tamoxifen plus ovarian function suppression, and exemestane plus ovarian function suppression in premenopausal women with hormone-responsive breast cancer.
- SOLAR-1Independent statistical analysis of the SOLAR-1 phase 3 trial of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer that progressed on or after aromatase inhibitor treatment.
- SOLEComplete statistical analysis of the SOLE phase 3 trial of continuous versus intermittent letrozole in postmenopausal women with hormone receptor-positive, lymph node-positive, early-stage breast cancer after prior hormone therapy.
- SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
- SOPHIAIndependent statistical analysis of the SOPHIA phase 3 trial of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer, including its randomized design, time-to-event endpoints, hazard ratios, confidence intervals,…
- SPARTANIndependent statistical analysis of the phase 3 SPARTAN trial of apalutamide versus placebo in men with non-metastatic castration-resistant prostate cancer, including metastasis-free survival, time to metastasis, progression-free survival, statistical methodology, safety, and…
- SPLASHIndependent statistical analysis of the phase 3 SPLASH trial evaluating [Lu-177]-PNT2002 in metastatic castration-resistant prostate cancer, including randomized design, radiographic progression-free survival, hazard-ratio methodology, and statistical interpretation.
- SPOTLIGHTComplete statistical analysis of the randomized phase 3 SPOTLIGHT trial of zolbetuximab plus chemotherapy versus placebo plus chemotherapy in adults with gastric or gastroesophageal junction adenocarcinoma, including progression-free survival, overall survival, response,…
- SUNLIGHTIndependent statistical analysis of the phase 3 SUNLIGHT trial of trifluridine/tipiracil with and without bevacizumab in refractory metastatic colorectal cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, and statistical interpretation.
- SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.
- TAILORxIndependent statistical analysis of the TAILORx phase 3 trial, focusing on 5-year disease-free survival, the Cox proportional-hazards model, hazard ratios, confidence intervals, and the trial's noninferiority design.
- TALAPRO-2Independent statistical analysis of TALAPRO-2, evaluating talazoparib plus enzalutamide versus placebo plus enzalutamide in mCRPC, with detailed interpretation of radiographic progression-free survival and the trial's survival-analysis methods.
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- TEXTIndependent statistical analysis of TEXT, a randomized phase 3 trial of triptorelin with either exemestane or tamoxifen in premenopausal women with hormone-responsive breast cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank…
- TH3RESAIndependent statistical analysis of TH3RESA, a randomized phase 3 trial of trastuzumab emtansine versus treatment of physician's choice in participants with HER2-positive breast cancer who had received at least two prior HER2-directed…
- THORComplete statistical analysis of the phase 3 THOR trial of erdafitinib in participants with advanced urothelial cancer and selected FGFR gene aberrations, including overall survival, trial design, statistical methodology, and interpretation.
- TITANIndependent statistical analysis of TITAN (NCT02489318), a randomized phase 3 trial of apalutamide plus androgen deprivation therapy versus androgen deprivation therapy in participants with metastatic hormone-sensitive prostate cancer.
- ToGAIndependent statistical analysis of the ToGA phase 3 trial of trastuzumab plus fluoropyrimidine/cisplatin versus fluoropyrimidine/cisplatin alone in patients with HER2-positive advanced gastric cancer, including survival, response, statistical methods, interpretation, and safety.
- TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.
- TRITON3Independent statistical analysis of TRITON3, a randomized phase 3 trial of rucaparib versus physician's choice of therapy in metastatic castration-resistant prostate cancer with BRCA or ATM alterations.
- TROPiCS-02Independent statistical analysis of TROPiCS-02, a randomized phase 3 trial of sacituzumab govitecan-hziy versus treatment of physician's choice in participants with HR+/HER2- metastatic breast cancer.
- TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.
- TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…
- VELIAIndependent statistical analysis of the VELIA phase 3 trial of veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage III or IV high-grade serous epithelial…
- VELOURIndependent statistical analysis of the phase 3 VELOUR trial of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in metastatic colorectal cancer after failure of an oxaliplatin-based regimen, including trial design, survival analysis,…
- VIALE-AIndependent statistical analysis of the phase 3 VIALE-A trial of venetoclax plus azacitidine versus azacitidine in treatment-naive participants with acute myeloid leukemia who are ineligible for standard induction therapy.
- VISIONIndependent statistical analysis of the VISION phase 3 trial of 177Lu-PSMA-617 plus best supportive/best standard of care in metastatic castrate-resistant prostate cancer, including randomized design, time-to-event endpoints, hazard ratios, response analyses, safety,…
- ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…